Form 8-K Valeant Pharmaceuticals For: Oct 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Valeant Pharma (VRX) Posts Strong Q3 Results, Bumps Outlook Higher; Aegis Capital Maintains at 'Buy'
October 20, 2014 9:55 AM EDTAegis Capital affirms its Buy rating and $180 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results and guidance update.
Analyst Ram Selvaraju commented, This morning, Valeant reported third quarter 2014 financial results. The firm delivered cash EPS of $2.11 per share vs. our projection of... More
